Reference:	FOI.9381.22	
Subject:	Non-tuberculosis mycobacterium treatments	
Date of Request:	13 July 2022	

Requested:

- 1. How many patients were treated in the last 12 months (for any disease) with:
 - a. Ethambutol + rifampicin + Clarithromycin/azithromycin
 - b. Ethambutol + rifampicin + Clarithromycin/azithromycin with the addition of injectable (IV) or nebulised Amikacin
- 2. How many patients have been diagnosed in the last 12 months for the following diseases?
 - a. Non-tuberculosis mycobacterium (NTM) (ICD10 codes: A31.0/A31.9)
 - b. Bronchiectasis (ICD10 codes J47/Q33.4)
- 3. Which other hospital trust or health care professional would you contact if you require advice on non-tuberculosis mycobacterium (NTM) infections?
- 4. Do you discuss difficult to manage non-tuberculosis mycobacterium (NTM) patients as a Multidisciplinary Team (MDT)?

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of prescriptions issued for the requested medications, for any disease, during the period 1 August 2021 to 31 July 2022.

Medication	Number
Ethambutol + rifampicin + Clarithromycin/azithromycin	6
Ethambutol + rifampicin + Clarithromycin/azithromycin with the addition of injectable (IV) or nebulised Amikacin	0

2. The UHB provides, within the table below, the number of patients diagnosed with Non-Tuberculosis Mycobacterium (NTM) (ICD10 codes: A31.0/A31.9) and Bronchiectasis (ICD10 codes J47/Q33.4), during the period 1 July 2021 to 30 June 2022.

Diagnosis	Number
NTM	4
Bronchiectasis	492

- 3. The UHB confirms that advice on NTM infections is often sought from the Lead Scientist and the Consultant in Microbiology in Cardiff and Vale University Health Board (CVUHB).
- 4. The UHB confirms that it attends a monthly All Wales Multidisciplinary Team (MDT) meeting where difficult to manage NTM cases can be discussed.